Medical Cost Trend Behind the Numbers 2017

Strictly Private and Confidential

HFMA
## Table of contents

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>The 101 – medical cost trend and our research</td>
</tr>
<tr>
<td>Putting trends in perspective</td>
</tr>
<tr>
<td>Factors affecting the 2017 spending growth rate - Inflators</td>
</tr>
<tr>
<td>Factors affecting the 2017 spending growth rate - Deflators</td>
</tr>
<tr>
<td>What this means for your business</td>
</tr>
</tbody>
</table>
About our report

• Conducted interviews with 12 health plan executives whose companies cover more than 100 million people

• Conducted interviews with internal PwC subject matter specialists covering payer, provider, pharma, and employer sectors

• Included results from PwC’s 2016 Health and Well-being Touchstone Survey of more than 1,100 employers from 36 industries, HRI consumer survey of more than 1,000 US adults, and an HRI survey of Health Plan Alliance members

• Analyzed government data, academic journal articles, industry trend reports and conference proceedings in determining the 2017 growth rate
# The 101: what is medical cost trend?

<table>
<thead>
<tr>
<th>Definition</th>
<th>Projected percentage increase in the cost to treat patients, or healthcare spending growth rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Importance</td>
<td>The projection is used by insurance companies and employers to calculate health plan premiums for the coming year</td>
</tr>
<tr>
<td>Influencers</td>
<td>Changes in the price of medical products and services, known as unit cost inflation</td>
</tr>
<tr>
<td></td>
<td>Changes in the number of services used, or per capita utilization increases</td>
</tr>
</tbody>
</table>
PwC’s HRI projects a 2017 medical cost trend of 6.5%—level with the 2016 projection

Source: PwC Health Research Institute medical cost trends 2007–2017
Recent trends in health insurance costs are at historical lows

Growth in health expenditures for private employers from 1961-2015

Source: PwC Health Research Institute analysis based on CMS National Health Expenditures Private Health Insurance Component data
Price, not utilization, is the historical force behind medical cost trend

Components of growth in healthcare costs from 2001-2015

Source: PwC Health Research Institute analysis of Bureau of Labor Statistics data
Roughly half of employer health costs stem from hospital inpatient and outpatient services; the prescription drug share is small but increasing

Share of employer healthcare spending in 2007 and projected 2017

Feedback from ACA health insurance exchanges

Adoption of private exchanges by employers
- The ACA exchanges attracted strong enrollment in their first few years
- Premiums are similar to or lower than those for comparable employer plans

Adoption of narrow networks by exchange enrollees
- Lower cost of narrow networks is appealing to employers
- Acceptance of narrow networks by exchange enrollees may encourage employers to introduce them

Employer cross-subsidization may decline in Medicaid expansion states
- Medicaid expansion can help reduce employer costs by one-half to one-third in states where uninsured are enrolled in both Medicaid and the exchanges
Inflator #1: Convenience has a cost

Use of retail clinics is increasing along with the number of places for treatment

Source: PwC Health Research Institute Consumer Survey and Convenient Care Association data
Inflator #2: The share of employer health spending on mental health services is increasing

Mental health spending as a share of total employer health spending from 2005-2013

Source: PwC Health Research Institute analysis based on Medical Expenditure Panel Survey data
**Inflator #2: The new focus on mental health parity will likely increase utilization in 2017**

**Timeline of mental health parity legislation**

- **2008**
  - Mental Health Parity Act amended to require full parity. Insurance companies must treat mental health conditions on an equal basis with physical conditions when health policies cover both.

- **2010**
  - The Patient Protection and Affordable Care Act was signed which required all health insurance plans to include coverage for the treatment of mental health and substance use disorders.

- **March 2016**
  - CMS finalizes mental health and substance use disorder parity rule for Medicaid and Children’s Health Insurance Program.

- **October 31, 2016**
  - The interagency task force will be responsible for delivering a report to the President.

- **2010**
  - The Patient Protection and Affordable Care Act was signed which required all health insurance plans to include coverage for the treatment of mental health and substance use disorders.

Source: PwC Health Research Institute analysis, Kaiser Family Foundation, Kaiser Health News and Health Affairs

Medical Cost Trend

PwC
**Deflator # 1: Interest in high performance networks has increased substantially**

As more employees push back against high cost sharing due to their inability to pay their deductibles, employers are exploring other ways to control costs.

### Already implemented a performance based network

<table>
<thead>
<tr>
<th>Year</th>
<th>Percent of Employers</th>
</tr>
</thead>
<tbody>
<tr>
<td>'14</td>
<td>3%</td>
</tr>
<tr>
<td>'15</td>
<td>6%</td>
</tr>
<tr>
<td>'16</td>
<td>9%</td>
</tr>
</tbody>
</table>

### Considering the implementation of a performance based network

<table>
<thead>
<tr>
<th>Year</th>
<th>Percent of Employers</th>
</tr>
</thead>
<tbody>
<tr>
<td>'14</td>
<td>34%</td>
</tr>
<tr>
<td>'15</td>
<td>37%</td>
</tr>
<tr>
<td>'16</td>
<td>43%</td>
</tr>
</tbody>
</table>

**Deflator # 2: PBM win price concessions**

The approval of a second specialty medication within a treatment class can give PBMs leverage to extract sizable rebates.

*Specialty drug M*, a direct competitor, gains FDA approval.

- **Specialty drug Z**, a first-in-class breakthrough therapy, has a list price of $60,000 for a course of treatment.
  - Discount = 5%
  - $57,000

- Specialty drug Z is limited to one treatment.
- Lowering the net cost of drug Z to $36,000.

- Discount = 40%
- PBMs act to limit formularies to one treatment, lowering the net cost of drug Z to $36,000.

*Source: PwC Health Research Institute*
Specialty drugs are loosening their grip on growth

The impact of Hepatitis C therapy on medical cost trend declines after 2016 as the number of patients treated declines.

Source: PwC Health Research Institute estimate based on National Health and Nutrition Examination Survey and 2012 Truven Health Analytics claims data from employers.
The impact of a new specialty drug entering the market can vary greatly depending on price and volume of sales.
Healthcare organizations are looking for new ways to reduce costs as consumerism and value forge ahead

**Employers**
1) Realign cost sharing on ambulatory services
2) Consider a high performance network arrangement
3) Evaluate PBM arrangements

**Healthcare providers**
1) Considering partnerships with insurers
2) Providing convenience that consumers are demanding
3) Collaborating with PBMs

**Health insurers**
1) Leveraging alternative therapies
2) Creating a framework for high performance networks
3) Reviewing PBM relationships

**Pharma and life sciences**
1) Developing an effective pricing strategy
2) Discussing new products with insurers and PBMs early
3) Considering the impression made by pricing decisions
Thank you!

To download the full report, please visit: www.pwc.com/us/medicalcosttrends